Experiences with a new ergoline (CF 25-397) in parkinsonism.
Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.
D000368:Aged; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism; D003680:Deglutition Disorders / Q000139:chemically induced; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004873:Ergolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D051381:Rats; D013045:Species Specificity; D013239:Stereotyped Behavior / Q000187:drug effects; D014202:Tremor / Q000188:drug therapy
D004873:Ergolines; D004298:Dopamine